CN114829370B - 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 - Google Patents

蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Info

Publication number
CN114829370B
CN114829370B CN202080074610.XA CN202080074610A CN114829370B CN 114829370 B CN114829370 B CN 114829370B CN 202080074610 A CN202080074610 A CN 202080074610A CN 114829370 B CN114829370 B CN 114829370B
Authority
CN
China
Prior art keywords
formula
pharmaceutically acceptable
degrees
crystalline form
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080074610.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114829370A (zh
Inventor
曹甘风
李群
张化平
于洪武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pruder Therapeutics Ltd
Original Assignee
Pruder Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pruder Therapeutics Ltd filed Critical Pruder Therapeutics Ltd
Publication of CN114829370A publication Critical patent/CN114829370A/zh
Application granted granted Critical
Publication of CN114829370B publication Critical patent/CN114829370B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN202080074610.XA 2019-09-18 2020-09-18 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 Active CN114829370B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902322P 2019-09-18 2019-09-18
US62/902,322 2019-09-18
PCT/US2020/051563 WO2021055797A1 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (2)

Publication Number Publication Date
CN114829370A CN114829370A (zh) 2022-07-29
CN114829370B true CN114829370B (zh) 2025-10-28

Family

ID=72717922

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074610.XA Active CN114829370B (zh) 2019-09-18 2020-09-18 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Country Status (12)

Country Link
US (2) US12414953B2 (cg-RX-API-DMAC10.html)
EP (1) EP4031555A1 (cg-RX-API-DMAC10.html)
JP (1) JP7706166B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220065811A (cg-RX-API-DMAC10.html)
CN (1) CN114829370B (cg-RX-API-DMAC10.html)
AU (1) AU2020349553B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022004630A2 (cg-RX-API-DMAC10.html)
CA (1) CA3154566A1 (cg-RX-API-DMAC10.html)
IL (1) IL291417B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022003340A (cg-RX-API-DMAC10.html)
WO (1) WO2021055797A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202203680B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971288A (zh) * 2018-03-14 2020-11-20 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AU2015301196A1 (en) * 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) * 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
WO2017206904A1 (zh) * 2016-06-02 2017-12-07 上海海雁医药科技有限公司 Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2017218802A1 (en) * 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112019006414A2 (pt) * 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
KR101785870B1 (ko) 2016-11-03 2017-10-13 한규락 오르골 장치
MA49840A (fr) * 2017-08-09 2020-06-17 Prelude Therapeutics Inc Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EP3700906A1 (en) * 2017-10-26 2020-09-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971288A (zh) * 2018-03-14 2020-11-20 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Also Published As

Publication number Publication date
JP2022548689A (ja) 2022-11-21
US20230029094A1 (en) 2023-01-26
CN114829370A (zh) 2022-07-29
ZA202203680B (en) 2025-12-17
US20250367205A1 (en) 2025-12-04
US12414953B2 (en) 2025-09-16
AU2020349553B2 (en) 2026-07-02
IL291417B2 (en) 2025-12-01
KR20220065811A (ko) 2022-05-20
MX2022003340A (es) 2022-06-14
WO2021055797A1 (en) 2021-03-25
CA3154566A1 (en) 2021-03-25
BR112022004630A2 (pt) 2022-05-31
AU2020349553A1 (en) 2022-04-07
WO2021055797A9 (en) 2021-04-22
EP4031555A1 (en) 2022-07-27
IL291417A (en) 2022-05-01
JP7706166B2 (ja) 2025-07-11
IL291417B1 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
EP4010080B1 (en) Heterocyclic compounds for use in the treatment of cancer
JP7328218B2 (ja) タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤
WO2019032859A1 (en) SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
JP6088542B2 (ja) Aktキナーゼ阻害剤としての置換イミダゾピラジン類
CN116583283B (zh) Cdk抑制剂及其作为药物的用途
EP3428158A1 (en) Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
EP4234547A2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
KR20200132916A (ko) 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
US20250367205A1 (en) Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
JP2025538228A (ja) Brm標的化化合物及び関連する使用方法
CN113811539A (zh) 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
WO2024086789A2 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
KR20210043635A (ko) B 세포 악성 종양의 치료
JP2025510738A (ja) 多型化合物及びその使用
EA044352B1 (ru) Селективные ингибиторы протеинаргининметил трансферазы 5 (prmt5)
CN115698024A (zh) 作为髓系细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物
AU2024302003A1 (en) Crystal form of enpp1 inhibitor
WO2024216249A1 (en) Cdk inhibitors and their use as pharmaceuticals
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
EA043295B1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant